"Tri S. Phillips on tutkinut borrelioosia 15 v. Hänen mukaansa borrelioosiin liittyy paljon väärää tietoa. Esim. vain n. 40 - 50 %:lle kehittyy pureman jälkeen ihomuutos. Joillekin antibioottihoidosta on apua eivätkä oireet enää palaa, mutta lukuisat tartunnan saaneet eivät ole näin onnekkaita. Tilannetta vaikeuttaa entisestään se tosiasia että nykyisistä testeistä yksikään ei pysty osoittamaan bakteerin olemassaoloa elimistössä riittävän luotettavasti.
Tauti aiheuttaa tyypillisesti oireita eri puolilla elimistöä; hermot, aivot, sydän, lihakset, nivelet jne. Oireet voivat välillä hävitä ja ilmestyä uudelleen, koska borreliabakteeri on yksisoluinen ja hitaasti kehittyvä. Toisin kuin useat ajattelevat, suonensisäinen antibioottihoito ei ole suun kautta otettua antibioottihoitoa tehokkaampaa. Phillipsin mukaan borrelioosiin ei ole olemassa mitään tiettyä hoitomuotoa, vaikka antibiooteista saattaakin olla apua. Borreliabakteerista on satoja toisistaan jonkin verran poikkeavia kantoja ja mm. sen vuoksi ihmiset reagoivat hoitoihin eri tavoin." ...
Lyme Disease Symposium raises concerns
By Nancy Robinson
Article Last Updated: 05/10/2007
Connecticut remains ground zero for Lyme disease, and it is a rare household that has not been touched by some aspect of this multi-faceted illness.
A distinguished panel of speakers, sponsored by the Democratic Town Committee, addressed an audience Tuesday night at Town Hall.
The speakers included Attorney General Richard Blumenthal, State Rep. William Tong (D-147), Dr. Leo J. Shea III, clinical assistant professor at Rusk Institute, and Dr. Steven Philips, a world-renowned expert on Lyme disease.
Phillips has studied Lyme disease for 15 years. He is past-president of the International Lyme and Associated Diseases Society (ILADS) which is dedicated to educating physicians about accurate diagnosis and appropriate treatment of Lyme and its associated diseases.
There is much misinformation surrounding this disease. For example, according to Phillips, only 40 to 50 percent of patients will develop the well-known bulls-eye rash. And while some people will respond to a treatment of antibiotics and will not suffer any reoccurrence, many others will not be so fortunate.
There are several hundred strains of Lyme, Phillips said, which is why people react differently to the treatment. To make the situation even more difficult, there is no blood test that will prove the presence of Lyme. Typically the disease presents itself as a multi-system illness that can affect the nerves, brain, heart, muscle and joints with a variety of symptoms. Symptoms can disappear then reappear because the illness is caused by a bacteria and single-cell organism that is slow-growing.
Contrary to what many people believe, statistics have shown that there is no advantage to oral versus intravenous treatment with antibiotics.
"There is no definitive therapy for Lyme disease, though antibiotics have proven helpful," Phillips said.
Shea, now serving as chairman of the National Research Fund for Tick-Borne Diseases (NRFTD), told the audience that Lyme disease first received recognition 30 years ago, though it had been around for decades before that. Lyme disease can result when a tick invades the body, causing an illness which often results in lingering effects from co-morbid infections.
Shea began his presentation by referring anecdotally to a situation that is common to many New Canaan residents.
"Some people react very well to a treatment of antibiotics, while others who receive the same treatment have lingering symptoms over many years," Shea said.
"Good, unbiased research is needed," he explained. Currently there is little or no funding from the federal government centered on research studies to help scientists understand this complex disease.
The NRFTD's mission is to support scientific research and understanding of the complicated infections caused by ticks. Shea also reported that all of the fund's six pilot projects underway will appear in peer-review journals, which is critical in acquiring more funding for additional research.
This factor is critical for two reasons. Viable, peer-reviewed projects that adhere to the highest standards of quality have a greater likelihood of receiving long-term funding by the National Institutes of Health or the National Science Foundation. In practical terms for sufferers of Lyme disease, these study results are examined by insurance companies, who have been criticized often for denying coverage to people receiving treatment for Lyme disease.
Also concerned about insurance coverage was Attorney General Richard Blumenthal, who reported that there was a systemic denial of coverage by insurance companies. Blumenthal said he believed people who were entitled to insurance coverage were being denied improperly. He has been on the forefront for several years in defending the rights of patients requiring treatment, including long-course and intravenous antibiotics.
"It is a legal mandate and a principle that qualified doctors and patients should decide on treatment, not insurance bureaucrats or public officials," he said.
Recently Blumenthal ordered civil investigation of the Infectious Disease Society of America's (IDSA) development of treatment guidelines for Lyme, which appeared to be overly negative and opposed to long-term antibiotic treatment.
Blumenthal discovered that in some cases panel members were consultants to firms that might possibly influence them to favor one treatment over another.
He also has been instrumental in requiring the reporting of pharmaceutical company payments to physicians.
Another area of concern is the need for ongoing regulation of the Department of Public Health, which is no longer required to report cases of Lyme disease in Connecticut, which can limit the help received from the federal government.
State Rep. William Tong is working closely with Attorney General Blumenthal on two legislative proposals.
Having contracted Lyme disease himself, Tong was one of the fortunate ones who responded to treatment and has not suffered a relapse.
"This is a scary, chronic condition that deserves attention and it has not received that attention here in Connecticut," said Tong.
In 2002, more than 4,600 cases of Lyme were reported and that is estimated to be only 10 percent of the active cases. In 2003 the DPW stopped mandatory reporting of cases and in 2005 only 1,500 cases were reported, even though Connecticut is No. 1 in the county in the rate of Lyme infection.
"You would think from those numbers that the problem has been solved, which we all know is not the case," Tong said.
Tong recently introduced a proposal in the state House that included reinstatement of mandatory lab reports of Lyme disease and another proposal that establishes a Connecticut Lyme Disease Task Force.
"We need a strategic plan for the diagnosis and treatment of Lyme because we are affected more than any other state," Tong said.